Current strategies for quantification of estrogens in clinical research

Nina Denver, Shazia Khan, Natalie Z.M. Homer, Margaret R. MacLean, Ruth Andrew

Research output: Contribution to journalArticle

Abstract

Estrogens and their bioactive metabolites play key roles in regulating diverse processes in health and disease. In particular, estrogens and estrogenic metabolites have shown both protective and non-protective effects on disease pathobiology, implicating the importance of this steroid pathway in disease diagnostics and monitoring. All estrogens circulate in a wide range of concentrations, which in some patient cohorts can be extremely low. However, elevated levels of estradiol are reported in disease. For example, in pulmonary arterial hypertension (PAH) elevated levels have been reported in men and postmenopausal women. Conventional immunoassay techniques have come under scrutiny, with their selectivity, accuracy and precision coming into question. Analytical methodologies such as gas and liquid chromatography coupled to single and tandem mass spectrometric approaches (GC–MS, GC–MS/MS, LC–MS and LC–MS/MS) have been developed to quantify endogenous estrogens and in some cases their bioactive metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid or solid-phase extraction approaches are favoured with derivatization remaining a necessity for detection in lower volumes of sample. The limits of quantitation of individual assays vary but are commonly in the range of 0.5–5 pg/mL for estrone and estradiol, with limits for their bioactive metabolites being higher. This review provides an overview of current approaches for measurement of unconjugated estrogens in biological matrices by MS, highlighting the advances in this field and the challenges remaining for routine use in the clinical and research environment.

LanguageEnglish
Article number105373
Number of pages12
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume192
Early online date19 May 2019
DOIs
Publication statusE-pub ahead of print - 19 May 2019

Fingerprint

Metabolites
Estrogens
Research
Estradiol
Estrone
Solid Phase Extraction
Liquid chromatography
Liquids
Saliva
Immunoassay
Pulmonary Hypertension
Gas chromatography
Gas Chromatography
Assays
Steroids
Health
Urine
Plasmas
Fluids
Monitoring

Keywords

  • bioactive metabolites
  • estrogen
  • disease pathobiology
  • steroid pathway
  • disease diagnostics
  • monitoring

Cite this

@article{1f341350b3844a38867457aa3de08234,
title = "Current strategies for quantification of estrogens in clinical research",
abstract = "Estrogens and their bioactive metabolites play key roles in regulating diverse processes in health and disease. In particular, estrogens and estrogenic metabolites have shown both protective and non-protective effects on disease pathobiology, implicating the importance of this steroid pathway in disease diagnostics and monitoring. All estrogens circulate in a wide range of concentrations, which in some patient cohorts can be extremely low. However, elevated levels of estradiol are reported in disease. For example, in pulmonary arterial hypertension (PAH) elevated levels have been reported in men and postmenopausal women. Conventional immunoassay techniques have come under scrutiny, with their selectivity, accuracy and precision coming into question. Analytical methodologies such as gas and liquid chromatography coupled to single and tandem mass spectrometric approaches (GC–MS, GC–MS/MS, LC–MS and LC–MS/MS) have been developed to quantify endogenous estrogens and in some cases their bioactive metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid or solid-phase extraction approaches are favoured with derivatization remaining a necessity for detection in lower volumes of sample. The limits of quantitation of individual assays vary but are commonly in the range of 0.5–5 pg/mL for estrone and estradiol, with limits for their bioactive metabolites being higher. This review provides an overview of current approaches for measurement of unconjugated estrogens in biological matrices by MS, highlighting the advances in this field and the challenges remaining for routine use in the clinical and research environment.",
keywords = "bioactive metabolites, estrogen, disease pathobiology, steroid pathway, disease diagnostics, monitoring",
author = "Nina Denver and Shazia Khan and Homer, {Natalie Z.M.} and MacLean, {Margaret R.} and Ruth Andrew",
year = "2019",
month = "5",
day = "19",
doi = "10.1016/j.jsbmb.2019.04.022",
language = "English",
volume = "192",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",

}

Current strategies for quantification of estrogens in clinical research. / Denver, Nina; Khan, Shazia; Homer, Natalie Z.M.; MacLean, Margaret R.; Andrew, Ruth.

In: Journal of Steroid Biochemistry and Molecular Biology , Vol. 192, 105373, 30.09.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Current strategies for quantification of estrogens in clinical research

AU - Denver, Nina

AU - Khan, Shazia

AU - Homer, Natalie Z.M.

AU - MacLean, Margaret R.

AU - Andrew, Ruth

PY - 2019/5/19

Y1 - 2019/5/19

N2 - Estrogens and their bioactive metabolites play key roles in regulating diverse processes in health and disease. In particular, estrogens and estrogenic metabolites have shown both protective and non-protective effects on disease pathobiology, implicating the importance of this steroid pathway in disease diagnostics and monitoring. All estrogens circulate in a wide range of concentrations, which in some patient cohorts can be extremely low. However, elevated levels of estradiol are reported in disease. For example, in pulmonary arterial hypertension (PAH) elevated levels have been reported in men and postmenopausal women. Conventional immunoassay techniques have come under scrutiny, with their selectivity, accuracy and precision coming into question. Analytical methodologies such as gas and liquid chromatography coupled to single and tandem mass spectrometric approaches (GC–MS, GC–MS/MS, LC–MS and LC–MS/MS) have been developed to quantify endogenous estrogens and in some cases their bioactive metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid or solid-phase extraction approaches are favoured with derivatization remaining a necessity for detection in lower volumes of sample. The limits of quantitation of individual assays vary but are commonly in the range of 0.5–5 pg/mL for estrone and estradiol, with limits for their bioactive metabolites being higher. This review provides an overview of current approaches for measurement of unconjugated estrogens in biological matrices by MS, highlighting the advances in this field and the challenges remaining for routine use in the clinical and research environment.

AB - Estrogens and their bioactive metabolites play key roles in regulating diverse processes in health and disease. In particular, estrogens and estrogenic metabolites have shown both protective and non-protective effects on disease pathobiology, implicating the importance of this steroid pathway in disease diagnostics and monitoring. All estrogens circulate in a wide range of concentrations, which in some patient cohorts can be extremely low. However, elevated levels of estradiol are reported in disease. For example, in pulmonary arterial hypertension (PAH) elevated levels have been reported in men and postmenopausal women. Conventional immunoassay techniques have come under scrutiny, with their selectivity, accuracy and precision coming into question. Analytical methodologies such as gas and liquid chromatography coupled to single and tandem mass spectrometric approaches (GC–MS, GC–MS/MS, LC–MS and LC–MS/MS) have been developed to quantify endogenous estrogens and in some cases their bioactive metabolites in biological fluids such as urine, serum, plasma and saliva. Liquid-liquid or solid-phase extraction approaches are favoured with derivatization remaining a necessity for detection in lower volumes of sample. The limits of quantitation of individual assays vary but are commonly in the range of 0.5–5 pg/mL for estrone and estradiol, with limits for their bioactive metabolites being higher. This review provides an overview of current approaches for measurement of unconjugated estrogens in biological matrices by MS, highlighting the advances in this field and the challenges remaining for routine use in the clinical and research environment.

KW - bioactive metabolites

KW - estrogen

KW - disease pathobiology

KW - steroid pathway

KW - disease diagnostics

KW - monitoring

UR - https://www.sciencedirect.com/journal/the-journal-of-steroid-biochemistry-and-molecular-biology

U2 - 10.1016/j.jsbmb.2019.04.022

DO - 10.1016/j.jsbmb.2019.04.022

M3 - Article

VL - 192

JO - Journal of Steroid Biochemistry and Molecular Biology

T2 - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

M1 - 105373

ER -